Aciphex Patent Case Will Continue On Enforceability Grounds
This article was originally published in The Pink Sheet Daily
Executive Summary
Eisai wins a summary judgment against Dr. Reddy’s and Teva on the validity of its rabeprazole patent but must go to trial on enforceability claims.
You may also be interested in...
Teva Granted ANDA Approval for Eisai's Aciphex
Although Teva's ANDA for rabeprazole delayed-release tablets (Eisai's Aciphex) has been approved, the company told "The Pink Sheet" DAILY Feb. 22 that it will not immediately launch the product
Teva Granted ANDA Approval for Eisai’s Aciphex
Patent litigation could impact possible launch of proton pump inhibitor.
Teva Granted ANDA Approval for Eisai’s Aciphex
Patent litigation could impact possible launch of proton pump inhibitor.